Lack of symptom control · people with mild to moderate esophagitis, symptomatic, aged > 18 years (mean age 73 years)
It is very uncertain whether abrupt discontinuation deprescribing changes lack of symptom control compared with continued use (very low certainty).
1 finding from 1 review
Adverse drug withdrawal events ‐ relapse (endoscopic findings) · people with mild to moderate esophagitis, symptomatic, aged > 18 years (mean age 73 years)
It is very uncertain whether abrupt discontinuation deprescribing changes adverse drug withdrawal events ‐ relapse (endoscopic findings) compared with continued use (very low certainty).
1 finding from 1 review
Exercise capacity · heart transplant recipients
1 finding from 1 review
Health‐related quality of life · heart transplant recipients
1 finding from 1 review
Outcomes1 · women with moderate or severe primary dysmenorrhoea
The review found no eligible studies for this question.
1 finding from 1 review
Dill seed versus placebo Pain score · women with moderate or severe primary dysmenorrhoea
11 findings from 1 review
Show 8 more findings
Relief of pain · women with moderate or severe primary dysmenorrhoea
Dietary supplements may leads to higher zataria versus placebo Pain relief compared with placebo (low certainty).
3 findings from 1 review
Zinc sulphate versus placebo Adverse effects · women with moderate or severe primary dysmenorrhoea
It is very uncertain whether dietary supplements changes zinc sulphate versus placebo Adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Ginger versus placebo Adverse effects · women with moderate or severe primary dysmenorrhoea
It is very uncertain whether dietary supplements changes ginger versus placebo Adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Participant's global assessment of improvement Non‐standardised scale5 · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Investigator's global assessment (IGA) of improvement Treatment 'success' as defined by IGA score decrease5 · Moderate and severe acne vulgaris
MAL‐PDT probably leads to higher investigator's global assessment (IGA) of improvement Treatment… compared with red light only (moderate certainty).
1 finding from 1 review
Participant's global assessment of improvement Non‐standardised scale5 · Moderate and severe acne vulgaris
ALA‐PDT showed no clear difference in participant's global assessment of improvement Non‐standardised scale5 compared with blue light only (low certainty).
1 finding from 1 review
Investigator‐assessed change in inflamed lesions (ILs) Lesion counts · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed percentage change in ILs Lesion counts · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed severe adverse effects Application site blister · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator's global assessment (IGA) of improvement Treatment 'success' as defined by IGA score decrease5 · Moderate and severe acne vulgaris
ALA‐PDT showed no clear difference in investigator's global assessment (IGA) of improvement Treatment… compared with blue light only (low certainty).
1 finding from 1 review
Lesion count · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed severe adverse effects Blistering or scarring · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Paticipant's global assessment of improvement ‐ Not measured · Moderate and severe acne vulgaris
The review found no eligible studies for this question.
1 finding from 1 review
Light therapies for acne 2016 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Investigator‐assessed change in inflamed lesions (ILs) Lesion counts · Moderate and severe acne vulgaris
1 finding from 1 review